Description
Why It’s Done:
The IHC – BCL-2 test is typically performed to:
• Diagnose and classify lymphomas, especially follicular lymphoma, diffuse large B-cell lymphoma, and others.
• Assess prognosis in certain cancers—BCL-2 positivity may be associated with more aggressive or treatment-resistant disease.
• Guide treatment decisions, especially in hematologic cancers and breast cancer.
• Differentiate between reactive and neoplastic lymphoid proliferations.
Preparation:
• No special preparation is needed from the patient.
• The test is conducted on a biopsy or surgical tissue sample, often from lymph nodes or tumors.
• Pre-biopsy instructions (such as fasting or pausing certain medications) may be necessary depending on the biopsy method.
• Inform your doctor about any current medications or medical history before undergoing the biopsy procedure.
